Últimos Artículos de Diabetes, Obesity and Metabolism
- Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetes
- Insulin‐like growth factor 2 alleviates metabolic inflammation and associated cognitive impairment in diet‐induced obesity mice
- Taxonomic and functional shifts in the microbiome of severely obese, prediabetic patients: Ketogenic diet versus energy‐matched standard diet
- Insulin therapy DE‐intensificAtion with iGlarLixi: A phase 4, open‐label, parallel‐group randomised controlled trial
- Associations between steatotic liver disease subtypes and incident diabetes in young Korean adults: A nationwide cohort study
- Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence
- Oxytocin levels do not change around a meal and correlate with reward‐driven caloric consumption in adults with obesity
- Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model
- Disentangling the relationship between glucose, insulin and brain health: A UK Biobank study
- Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice
- Impact of stepwise diabetes technology advances in older adults with type 1 diabetes: A systematic review and meta‐analysis of randomised trials
- Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia
- Efficacy and safety of novel lipoprotein(a)‐targeted therapies: A systematic review and meta‐analysis of randomised controlled trials
- Efficacy and hypoglycaemia outcomes of once‐weekly insulin icodec versus once‐daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1–5
- Effectiveness and safety of saroglitazar in managing dyslipidaemia and liver enzymes in patients with type 2 diabetes, MASLD, and Stage 3 chronic kidney disease: A 12‐month observational study
- No causal link between the supply of GLP‐1 receptor agonists and antidepressants: Real‐world evidence from the Australian Pharmaceutical Benefits Scheme
- Explainable machine learning‐driven predictive modelling of incident cognitive impairment in individuals with early‐stage cardiovascular–kidney–metabolic syndrome: Insights from a longitudinal CHARLS cohort study
- Aldosterone antagonist combined with a SGLT2 inhibitor versus SGLT2 inhibitor monotherapy: An updated meta‐analysis
- Clinical implications of intentional weight loss in people living with type 2 diabetes: A real‐world database study
- Hypobaric hypoxia disrupts brown adipose thermogenic function in mice via Plin2 upregulation